Advisory Panel Endorses OraSure In-Home HIV Test
This article was originally published in The Tan Sheet
Executive Summary
An FDA advisory committee endorses OraSure’s OraQuick in-home HIV test in a unanimous vote. If approved, OraQuick would be the first OTC test for HIV that untrained users can perform entirely in the home.
You may also be interested in...
OraSure Plans To File Over-The-Counter HIV Test Application By Year End
OraSure Technologies says it expects this year to complete a pre-market application for its OraQuick Advance Rapid HIV-1 and -2 over-the-counter saliva test. The product would be the first HIV diagnostic intended for use at home and providing results directly to the user.
CDRH Focusing On New PMA Pathway, Clinical Trials Program In 2014/2015 Priorities
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.
FDA Emphasizes “Deregulatory” Efforts In Mobile Medical Apps Final Guidance
In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA had waited.